Clinical Trials on Non-resectable Disease

Total 378743 results

Delcath Systems Inc.

Unknown

Registry Protocol- Melphalan Percutaneous Hepatic Perfusion for the Treatment of Unresectable Hepatic Malignancy

Hepatic Malignant Neoplasm Primary Non-Resectable

United Kingdom
Centre Hospitalier Universitaire Dijon

Terminated

Viewpoints on the Social Representations and Rationale Concerning the Choices of Patients, Doctors and Caregivers With Regard to the Management of Patients With Non-resectable Metastatic Cancer of the Colon, Stomach, Bile Ducts, Rectum, Pancreas or Lung, or Gastrointestinal Neuroendocrine Tumours (EOLE)

Non-resectable Metastatic Cancer of the Lung | Non-resectable Metastatic Cancer of the Colon | Non-resectable Metastatic Cancer of the Rectosigmoid Junction | Non-resectable Metastatic Cancer of the Stomach | Non-resectable Metastatic Cancer of the Bile Duct | Non-resectable Metastatic Cancer... and other conditions

France
Lawson Health Research Institute

Recruiting

Model to Predict pCR and IrAEs in Early Stage Non-small Cell Lung Cancer (Pre-PLaN)

Non-small Cell Lung Cancer Stage IB (Resectable) | Non-small Cell Lung Cancer Stage II (Resectable) | Non-small Cell Lung Cancer Stage ⅢA (Resectable)

Canada
Massachusetts General Hospital

Terminated

A Pilot Study of Neoadjuvant Therapy With Gemcitabine and Cisplatin in Patients With Resectable or Unresectable Intrahepatic Cholangiocarcinoma

Resectable Intrahepatic Cholangiocarcinoma | Unresectable Intrahepatic Cholangiocarcinoma

United States
Weill Medical College of Cornell University

Terminated

RFA RCT for Pancreatic or Bile Duct Cancer (RFARCT)

Cholangiocarcinoma Non-resectable | Unresectable Pancreatic Cancer

United States
University Hospital, Montpellier
Federation Francophone de Cancerologie Digestive

Recruiting

Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma (GEMOXIA-02)

Cholangiocarcinoma Non-resectable | Non-metastatic

France
IRCCS San Raffaele

Completed

EUS-Guided Cryothermal Ablation in Patients With Stage III Pancreatic Adenocarcinoma (HybridTherm Study)

Pancreatic Adenocarcinoma Non-resectable

Italy
First People's Hospital of Hangzhou

Completed

EUS-RFA for Unresectable Pancreatic Ductal Adenocarcinoma

Pancreatic Adenocarcinoma Non-resectable

China
Medical University of South Carolina

Completed

A Study of Vaccination With Poly-ICLC and Dendritic Cells in Patients With Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma Non-resectable

United States
Hepatopancreatobiliary Surgery Institute of Gansu...

Recruiting

Photodynamic Therapy for Cholangiocarcinoma

Cholangiocarcinoma Non-resectable

China
West China Hospital

Recruiting

Cadonilimab With Chemotherapy in Treating Advanced Biliary Cancer

Cholangiocarcinoma Non-resectable

China
Blueprint Medicines Corporation

Completed

A Drug-drug Interaction Study of Avapritinib and Midazolam

Gastrointestinal Stromal Tumors | GIST | Non-resectable Advanced Solid Tumors | Recurrent or Unresectable Central Nervous System (CNS) Tumors

United States
PsiOxus Therapeutics Ltd

Completed

Mechanism of Action Trial of ColoAd1 (MOA)

Resectable Colon Cancer | Resectable Non-small Cell Lung Cancer | Resectable Bladder Cancer | Resectable Renal Cell Carcinoma

Spain
Beijing 302 Hospital

Not yet recruiting

Non-inferiority Study of Unresectable Hepatocelluar Carcinoma Receiving Stereotactic Radiotherapy Combined With Hepatic Arterial Chemoembolization Compared With Conversion Hepatectomy

Hepatocellular Carcinoma Non-resectable | Conversion
Xiangya Hospital of Central South University

Recruiting

Efficacy and Safety of NSCLC Patients With/Without Adjuvant Immunotherapy Who Have Achieved pCR After Neoadjuvant Immunotherapy

Resectable/Potentially Resectable NSCLC

China
Ze-yang Ding, MD
Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer (CCGLC)

Recruiting

Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma (CCGLC-013)

Cholangiocarcinoma Non-resectable

China
Ze-yang Ding, MD
Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer (CCGLC)

Recruiting

DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma (CCGLC-009)

Cholangiocarcinoma Non-resectable

China
Servier

Active, not recruiting

A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation

Cholangiocarcinoma Non-resectable | Cholangiocarcinoma Metastatic

Japan
Weill Medical College of Cornell University

Unknown

EUS BD vs ERCP TP for Pancreatic Cancer (BILPAL)

Pancreatic Cancer | Pancreatic Adenocarcinoma | Periampullary Cancer | Biliary Tract Neoplasms | Unresectable Pancreatic Cancer | Biliary Duct Obstruction | Periampullary Carcinoma Non-Resectable

United States
Omega Therapeutics

Recruiting

A Phase 1/2 Study to Evaluate OTX-2002 in Patients With Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association With the MYC Oncogene (MYCHELANGELO I)

Hepatocellular Carcinoma | Solid Tumor | Liver Cancer | Hepatocellular Carcinoma Non-resectable | Hepatocellular Cancer | Hepatocellular Carcinoma Recurrent | Liver, Cancer of, Non-Resectable

United States, Hong Kong, Korea, Republic of, Singapore, Taiwan
Tongji Hospital
Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer (CCGLC)

Recruiting

Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma (CCGLC-012)

Cholangiocarcinoma Non-resectable

China
University Health Network, Toronto

Recruiting

FAZA PET/MRI Pancreas

Locally Advanced Pancreatic Adenocarcinoma | Unresectable Pancreatic Cancer | Pancreatic Adenocarcinoma Non-resectable

Canada
Sandy Srinivas
GlaxoSmithKline

Completed

Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer

Bladder Cancer | Bladder (Urothelial, Transitional Cell) Cancer | Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy) | Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) | Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable

United States
Terumo Europe N.V.

Terminated

QuiremSpheres Observational Study (Hope166)

Liver, Cancer of, Non-Resectable

Netherlands, Germany
Fuda Cancer Hospital, Guangzhou
Shengxin Biotechnology Institute, Beijing

Completed

Bioinformation Therapy for Liver Cancer

Liver, Cancer of, Non-Resectable

China
Institut Bergonié
Novartis; Chugai Pharma France

Recruiting

Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas (CIRSARC)

Resectable | Non-metastatic Soft-tissue Sarcoma

France
Children's Oncology Group
National Cancer Institute (NCI)

Not yet recruiting

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

Metastatic Osteosarcoma | Localized Osteosarcoma | Unresectable Osteosarcoma | Resectable Osteosarcoma
Centre Leon Berard
CREATIS Laboratory

Completed

Phase 2 Study Evaluating Mid-position Strategy in Radiotherapy Treatment for Patients With a Locally Advanced Non-small Cell Lung Carcinoma (midP)

Non-small Cell Lung Cancer | Radiation Therapy | Locally Advanced Disease | Non-metastatic Disease | Non-resectable Disease

France
Halozyme Therapeutics

Terminated

Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, Intrahepatic | Gallbladder Adenocarcinoma

United States, Korea, Republic of, Thailand
Assistance Publique - Hôpitaux de Paris
AstraZeneca

Recruiting

Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation (DUMELEP)

BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA

France
The Netherlands Cancer Institute
Agenus Inc.

Recruiting

Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations (NEOASIS)

Resectable MMR-deficient Solid Tumors | Resectable MMR-proficient Solid Tumors

Netherlands
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Impact of Surgical Approach on Adaptation of Posture-respiratory Coupling (VaPosVent)

Resectable Lung Non-Small Cell Carcinoma

France
Emory University
National Cancer Institute (NCI)

Not yet recruiting

Proton Beam Radiation Therapy After Treatment for Resected N2 Non-Small Cell Lung Cancer

Resectable Lung Non-Small Cell Carcinoma

United States
Galera Therapeutics, Inc.

Terminated

Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer

Unresectable Pancreatic Cancer | Borderline Resectable Pancreatic Cancer | SBRT

United States, France, United Kingdom, Canada
RedHill Biopharma Limited

Completed

A Study of ABC294640 (Yeliva ®) Alone and in Combination With Hydroxychloroquine Sulfate in Treatment of Patients With Advanced Cholangiocarcinoma

Cholangiocarcinoma | Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Perihilar | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, Intrahepatic

United States
RedHill Biopharma Limited

Available

Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)

Cholangiocarcinoma | Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Perihilar | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, Intrahepatic
Scripps Health

Terminated

PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer (HALO-IST)

Pancreatic Adenocarcinoma Non-resectable

United States
Regeneron Pharmaceuticals

Not yet recruiting

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-small Cell Lung Cancer That Can be Treated With Surgery.

Resectable Non-small Cell Lung Cancer
Genta Incorporated

Unknown

Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer | Locally Advanced Non-resectable Breast Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb; Mirati Therapeutics Inc.

Recruiting

Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab (Neo-Kan)

Resectable Non-Small Cell Lung Cancer

United States
AVAX Technologies

Terminated

DNP-Modified Autologous Tumor Cell Vaccine for Resectable Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer - Completely Resectable

United States
City of Hope Medical Center
National Cancer Institute (NCI); Genentech, Inc.

Recruiting

Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC

Locally Advanced Skin Squamous Cell Carcinoma | Unresectable Skin Squamous Cell Carcinoma | Resectable Skin Squamous Cell Carcinoma

United States
Bristol-Myers Squibb

Recruiting

An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany (NENI)

Resectable Non-small Cell Lung Cancer

Germany
Akeso

Not yet recruiting

AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC

Resectable Non-small Cell Lung Cancer
Methodist Health System

Completed

TheraSphere & Treatment of Unresectable Primary or Unresectable Secondary Liver Cancer

Liver, Cancer of, Non-Resectable

United States
Gilead Sciences
Arcus Biosciences, Inc.

Recruiting

Study of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung)

Lung Cancer | Advanced or Metastatic Non-Small-Cell Lung Cancer | Resectable Non-Small-Cell Lung Cancer

United States, Korea, Republic of, Taiwan, Hong Kong, Israel, United Kingdom
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial

Potentially Resectable ALK Positive Non-Small Cell Lung Cancer
Shandong Cancer Hospital and Institute

Recruiting

Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC

Neoadjuvant Therapy | Resectable Lung Non-Small Cell Carcinoma | IMMUNOTHERAPY | Biomarkers / Blood

China
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Ganglioneuroblastoma

United States, Canada, Saudi Arabia, Puerto Rico, Australia, New Zealand
AIO-Studien-gGmbH
Servier

Completed

Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies (NALIRICC)

Cholangiocarcinoma Non-resectable | Cholangiocarcinoma of the Gallbladder | Cholangiocarcinoma Metastatic | Cholangiocarcinoma Advanced

Germany

Clinical Trials on Non-resectable Disease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations